MLTX MoonLake Immunotherapeutics AG: Accounting Value per Share

Graphic logo of MoonLake Immunotherapeutics (MLTX)

The share price history of MoonLake Immunotherapeutics (MLTX), which specializes in metabolic dysfunction therapy, currently stands at 5.16. Developing immune therapies involves colossal scientific challenges and pressure from corporate behemoths. Business prospects depend on the regulatory approval of sonelokimab and the rate of cash burn. Despite fresh investments, uncertainty remains regarding the outcome of final tests and the threat of acquisition by major players.

MoonLake Immunotherapeutics AG (MLTX): Share Book Value from 04/28/2023 to 10/28/2026

moonlaketx.com - analytical breakdowns and key metrics (MLTX)

- price and consensus price forecast:
Stock Quotes MoonLake Pharma|MLTX - Analyst Forecast Prices
- market capitalization data:
Market Valuation MoonLake|MLTX - Business Value
- book capitalization data:
Net Assets per Single Share MoonLake Immunotherapeutics|MLTX - Net Asset Value|Market Capitalization to Book Value Ratio moonlaketx.com|MLTX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Capital|Short-Term Debt to Equity MoonLake|MLTX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio MoonLake|MLTX - Company Long-Term Liabilities|Company Short-Term Debts MoonLake Immunotherapeutics
Fundamental company valuation:MoonLake Pharma - MLTX
Manufactured products of MoonLake

For the biotechnology company MoonLake Immunotherapeutics (MLTX), the net asset value per share reflects the intrinsic value of the business. This metric is calculated by dividing total equity minus liabilities by the number of outstanding securities, demonstrating the actual value of an investor's stake in the event of company liquidation. For the developer of Sonelokimab, growth in this indicator confirms the effective accumulation of resources to capture the immunology market. The stable trend on this chart minimizes the risks of significant capital drawdowns.

Competitors of MoonLake Immunotherapeutics (MLTX)

Accounting Value per Share Ascendis Pharma Inc. ASND|Madrigal Corp (MDGL) - Book Price of a Share|Accounting Value per Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|Crinetics Pharma (CRNX) - Book Value per Share|Accounting Value of a Share NewAmsterdam Pharma Corp (NAMS)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS